Business
Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
Novo Nordisk today announced new data on the investigational oral semaglutide 25 mg will be among 23 abstracts to be presented at ObesityWeek® from 4-7 November in Atlanta, US. The presentations will add to expanding the evidence base on Wegovy®'s overall weight loss efficacy and cardiometabolic profile, and showcase the innovative pipeline with new data for people living with obesity.
About this update from Novo Nordisk A/s Class B
[{"type":"list","items":[{"val":[{"type":"text","content":"New data from OASIS 4 on oral semaglutide 25 mg to reveal insights on cardiometabolic health among adults with obesity or overweight ","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional trial insights into impact on ability to do everyday activities and women's health among adults with obesity or overweight will also be shared 1-3 ","length":162,"tagName":"p"}]},{"val":[{"type":"text","content":"New CagriSema data from REDEFINE to be presented, highlighting innovative pipeline4,5","length":85,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":379,"olType":false},{"type":"text","content":"PLAINSBORO, N.J., and BAGSVÆRD, Denmark, Oct. 20, 2025 /PRNewswire/ -- Novo Nordisk today announced new data on the investigational oral semaglutide 25 mg will be among 23 abstracts to be presented at ObesityWeek® from 4-7 November in Atlanta, US. The presentations will add to expanding the evidence base on Wegovy®'s overall weight loss efficacy and cardiometabolic profile, and showcase the innovative pipeline with new data for people living with obesity.","length":469,"tagName":"p"},{"type":"text","content":""Our diverse range of abstracts reflects the strong momentum of our obesity portfolio and our dedication to improve the lives of people living with obesity. These data reinforce the established efficacy of the semaglutide molecule and highlight the increasing interest within the obesity community in oral options and dosing regimens that may better meet patients' health needs," said Martin Holst Lange, chief scientific officer and executive vice president, Research & Development at Novo Nordisk. "This builds on our longstanding track record of prioritizing ObesityWeek® by presenting new science that can make a real difference in patient care. As a pioneer with more than 25 years in obesity, we are proud to again be part of this key event, dedicated to advancing the understanding of obesity as a serious chronic disease."","length":863,"tagName":"p"},{"type":"text","content":"OASIS 4 trial highlights include:","length":33,"tagName":"p"},{"type":"text","content":"Investigating improvements in blood sugar and cardiovascular risk factorsIn an OASIS 4 post hoc analysis, investigators explored improvements in glycemic parameters and card...